Compare AbCellera Biologics Inc (ABCL) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ross Stores, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Ross Stores, Inc. trades at $216.37 (market cap $68.86B). The key difference: Ross Stores, Inc. is far larger — about 29.3× AbCellera Biologics Inc's market cap, and Ross Stores, Inc. pays a 0.83% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ROST | |
|---|---|---|
Market Cap | $2.35B | $68.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $240.13 |
52-Week Low | $2.78 | $127.59 |
Enterprise Value | $1.99B | $69.45B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Ross Stores (ROST) trades at $214.67, up 0.58% today, with strong fundamentals including 9.74% net income margin and 38.98% ROE. Recent earnings beats and a consensus price target of $259.00 suggest upside potential. Technicals are bearish near-term, but positive news highlights robust sales growth and expansion. Cash flow trends show volatility, with 2025 net cash flow negative but projected to rebound in 2026.
Outlook is positive driven by earnings momentum and store expansion, but risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is bullish with 64% buy ratings, supporting a growth-oriented view for investors seeking retail exposure with solid profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
